Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Sells $651,780.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Kymera Therapeutics Stock Up 5.6 %

KYMR stock opened at $49.03 on Friday. Kymera Therapeutics, Inc. has a 12 month low of $9.60 and a 12 month high of $50.69. The firm has a 50 day moving average of $44.93 and a two-hundred day moving average of $38.97. The company has a market capitalization of $3.01 billion, a price-to-earnings ratio of -19.53 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.10. The business had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. Kymera Therapeutics’s revenue was up 55.2% compared to the same quarter last year. During the same period last year, the business posted ($0.67) EPS. On average, research analysts expect that Kymera Therapeutics, Inc. will post -2.87 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Leerink Partners reaffirmed an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Monday, September 9th. HC Wainwright restated a “buy” rating and set a $46.00 price objective on shares of Kymera Therapeutics in a research report on Monday, June 17th. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, August 26th. Wells Fargo & Company increased their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Finally, B. Riley upped their price objective on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, July 9th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $48.67.

Institutional Trading of Kymera Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kymera Therapeutics by 18.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock worth $254,548,000 after buying an additional 996,300 shares during the last quarter. Vanguard Group Inc. raised its holdings in Kymera Therapeutics by 19.2% in the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after acquiring an additional 769,486 shares in the last quarter. Norges Bank acquired a new position in shares of Kymera Therapeutics in the fourth quarter valued at $12,834,000. Artal Group S.A. lifted its position in Kymera Therapeutics by 19.6% in the first quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock worth $121,691,000 after purchasing an additional 496,400 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Kymera Therapeutics by 229.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 674,655 shares of the company’s stock worth $17,177,000 after buying an additional 469,947 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.